Nabriva is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections.
Zavante is a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.
Zavante was advised by a Matheson team which included Corporate M&A Partners, Fergus Bolster and Patrick Spicer, West Coast based Tax Partner, Mark O’Sullivan and Tax Partner Vahan Tchrakian.